<DOC>
	<DOCNO>NCT00426647</DOCNO>
	<brief_summary>The primary objective equivalence study evaluate efficacy Norspan® patch versus Tramadol subject chronic , moderate severe osteoarthritis pain hip , knee and/or lumbar spine . The secondary objective evaluate safety general satisfaction patient two treatment group .</brief_summary>
	<brief_title>Norspan® Patches Versus Tramadol Subjects With Chronic , Moderate Severe Osteoarthritis Pain Hip Knee and/or Lumbar Spine</brief_title>
	<detailed_description>This randomise , double-blind , multicentre equivalence study active comparator , parallel group , evaluate efficacy safety Norspan® patch versus Tramadol subject OA pain hip , knee and/or lumbar spine , currently receive sub-optimal analgesic treatment ( define BS-11 score &gt; 4 ) treat paracetamol 4000 mg/day another analgesic least comparable . The study consist 4 phase : Run-in , Wash-out , Double blind Follow-up</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Males female age 18 year ( woman childbearing potential must negative pregnancy test , nonlactating , willing use adequate reliable contraception ( define IUD , contraceptive pill depot gestagen ) throughout study ) osteoarthritis hip &amp; /or knee . Or Males &amp; female age 50 year osteoarthritis lumbar spine without nerve root pressure . 2 . Clinical diagnosis OA hip and/or knee include fulfilment ACRcriteria radiographic MRScan evidence primary OAjoint hip &amp; /or knee . Or Clinical diagnosis OA lumbar spine without nerve root pressure , &amp; radiographic CTscan evidence lumbar OA . 3 . Subjects moderate severe pain confirm BS11 score &gt; 4 pain average primary OAjoint last 5 day prior Baseline Visit ( Randomisation Visit/Visit 4 ) . 4 . Subjects must previously WashoutPhase treat 4000 mg Paracetamol IR daily another analgesic treatment least comparable adequately pain relieved ( defined BS11 score &gt; 4 pain average Primary OAjoint 5 continuous day ) treatment . 5 . Subjects must willing discontinue analgesic ( incl . glucosamine ) PreScreening Visit ( Visit 1 ) Completion/Discontinuation Visit ( Visit 10 ) . 6 . Subjects must able read comprehend Danish willing sign inform consent . 7 . Subjects must willing able fill Subject Diary daily basis . 1 . Subjects treat highpotent opioid analgesic ( e.g . morphine , fentanyl , oxycodone , methadone , hydromorphone , ketobemidone , buprenorphine ( incl . Norspan® patch ) ) OA pain . Except subject treat highpotent opioid analgesic four continuous week OA pain beyond 3 month prior Prescreening Visit . 2 . Subjects treat highpotent opioid analgesic ( e.g . morphine , fentanyl , oxycodone , methadone , hydromorphone , ketobemidone , buprenorphine ( incl . Norspan® patch ) ) within four week prior Prescreening Visit due nonOA pain . 3 . Subjects treat 200 mg Tramadol daily 200 mg codeine daily last two week prior Prescreening Visit . 4 . History chronic condition ( ) , addition OA , require frequent analgesic therapy ( e.g . frequent headache , frequent migraine , gout , rheumatoid arthritis ) severe respiratory disease . 5 . Scheduled surgery would fall within phase ( RuninPhase , WashoutPhase , DoubleBlindPhase FollowupPhase ) study . 6 . Substance alcohol abuse , subject , opinion Investigator , demonstrate addictive substance abuse behaviour . 7 . Subjects cancer ( except basal cell carcinoma ) history cancer last 5 year ( except treat basal cell carcinoma ) . 8 . Untreated depression psychiatric disorder way participation study may , opinion Investigator , pose unacceptable risk subject . 9 . Dermatological disorder relevant patch application site precludes proper placement and/or rotation patch placement . 10 . Treatment steroid ( oral , intramuscular , intravenous , intraarticular , epidural , corticosteroid injection ) within 6 week prior Prescreening Visit study . 11 . Intraarticular hyaluron acid injection give within 6 month prior Prescreening Visit study . 12 . Any joint evacuation carry within 6 week prior Prescreening Visit study . 13 . Subjects currently take monoamine oxidase inhibitor ( MAOIs ) take MAOIs within 2 week prior Prescreening Visit . 14 . Participation clinical research study involve new chemical entity within 3 month prior Prescreening Visit . 15 . Allergies contraindication transdermal system patch adhesive . 16 . Known lack tolerance and/or effect Tramadol . 17 . Known hypersensitivity ( allergic reaction ) opioids Paracetamol . 18 . Ongoing requirement treatment direct external heat source heat lamp , electric blanket , sauna , heat pad heat waterbeds . 19 . New physiotherapy and/or chiropractic and/or non pharmacological regimen schedule commence RuninPhase , WashoutPhase DoubleBlindPhase study . This include physiotherapy and/or chiropractic and/or non pharmacological regimen schedule weekly window . 20 . Subjects cut hair patch site proper placement patch . 21 . Any contraindication list Summary Product Characteristics Norspan® patch Tramadol . 22 . Subjects , unsuitable reason participate study opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Pain</keyword>
	<keyword>Norspan</keyword>
	<keyword>Buprenorphine</keyword>
	<keyword>Tramadol</keyword>
</DOC>